Neelu Puri
Overview
Explore the profile of Neelu Puri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
924
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Deb S, Berei J, Miliavski E, Khan M, Broder T, Akurugo T, et al.
Cells
. 2024 Jun;
13(11.
PMID: 38891017
Telomeres, potential biomarkers of aging, are known to shorten with continued cigarette smoke exposure. In order to further investigate this process and its impact on cellular stress and inflammation, we...
2.
Racherla K, Dovalovsky K, Patel M, Harper E, Barnard J, Nasifuzzaman S, et al.
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444572
Osimertinib, an irreversible tyrosine kinase inhibitor, is a first-line therapy in EGFR-mutant NSCLC patients. Prolonged treatment with Osimertinib leads to resistance due to an acquired C797S mutation in the EGFR...
3.
Rager T, Eckburg A, Patel M, Qiu R, Gantiwala S, Dovalovsky K, et al.
Cancers (Basel)
. 2022 Aug;
14(15).
PMID: 35954441
Melanoma possesses invasive metastatic growth patterns and is one of the most aggressive types of skin cancer. In 2021, it is estimated that 7180 deaths were attributed to melanoma in...
4.
Osude C, Lin L, Patel M, Eckburg A, Berei J, Kuckovic A, et al.
Cells
. 2022 May;
11(10).
PMID: 35626731
NSCLC treatment includes targeting of EGFR with tyrosine kinase inhibitors (TKIs) such as Erlotinib; however, resistance to TKIs is commonly acquired through T790M EGFR mutations or overexpression of vascular endothelial...
5.
Patel M, Eckburg A, Gantiwala S, Hart Z, Dein J, Lam K, et al.
Cancers (Basel)
. 2021 Apr;
13(5).
PMID: 33807778
Malignant melanoma is the most aggressive type of skin cancer with invasive growth patterns. In 2021, 106,110 patients are projected to be diagnosed with melanoma, out of which 7180 are...
6.
Crees Z, Shearrow C, Lin L, Girard J, Arasi K, Bhoraskar A, et al.
Ther Adv Med Oncol
. 2020 Sep;
12:1758835920953731.
PMID: 32973931
Background: EGFR/c-Met activation/amplification and co-expression, mTOR upregulation/activation, and Akt/Wnt signaling upregulation have been individually associated with more aggressive disease and characterized as potential prognostic markers for lung cancer patients. Methods:...
7.
Eckburg A, Dein J, Berei J, Schrank Z, Puri N
Cancers (Basel)
. 2020 Aug;
12(9).
PMID: 32825005
Telomerase provides cancer cells with replicative immortality, and its overexpression serves as a near-universal marker of cancer. Anti-cancer therapeutics targeting telomerase have garnered interest as possible alternatives to chemotherapy and...
8.
Berei J, Eckburg A, Miliavski E, Anderson A, Miller R, Dein J, et al.
Curr Top Med Chem
. 2020 Jan;
20(6):458-484.
PMID: 31916516
Telomeres function as protective caps at the terminal portion of chromosomes, containing non-coding nucleotide sequence repeats. As part of their protective function, telomeres preserve genomic integrity and minimize chromosomal exposure,...
9.
Schrank Z, Khan N, Osude C, Singh S, Miller R, Merrick C, et al.
Molecules
. 2018 Sep;
23(9).
PMID: 30189661
Telomeres and telomerase have become attractive targets for the development of anticancer therapeutics due to their involvement in cancer cell immortality. Currently, several therapeutics have been developed that directly target...
10.
Schrank Z, Chhabra G, Lin L, Iderzorig T, Osude C, Khan N, et al.
Cancers (Basel)
. 2018 Jul;
10(7).
PMID: 29973561
Lung cancer is treated with many conventional therapies, such as surgery, radiation, and chemotherapy. However, these therapies have multiple undesirable side effects. To bypass the side effects elicited by these...